Tags

Type your tag names separated by a space and hit enter

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Neuroreport. 2009 Sep 23; 20(14):1265-9.N

Abstract

Dopamine replacement therapy for the treatment of Parkinson's disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 receptor-mediated signaling. Recent evidence suggests stimulation of striatal serotonin (5-HT) 1B receptors may reduce D1-mediated signaling. Given this potential antidyskinetic mechanism, male hemiparkinsonian Sprague-Dawley rats received treatments of D1 receptor agonist, SKF81297, (0.8 mg/kg) or L-DOPA (12 mg/kg, subcutaneous injection). Dyskinetic movements were rated using the AIMs scale. Rats were then administered vehicle (100% dimethyl sulfoxide) or the 5-HT1B receptor agonist, CP94253, (1.5 or 3.0 mg/kg, subcutaneous injection), followed by SKF81297 or L-DOPA and rated for AIMs. Results indicate that CP94253 mitigates both L-DOPA and D1 receptor agonist-induced dyskinesia. These findings suggest that 5-HT1B receptor stimulation directly diminishes D1 receptor-mediated dyskinesia, implicating an important target for the treatment of L-DOPA-induced dyskinesia.

Links

Aggregator Full Text

Authors+Show Affiliations

Jaunarajs KL
Department of Psychology, Binghamton University, State University of New York, Binghamton, New York 13902, USA.
Dupre KB
No affiliation info available
Steiniger A
No affiliation info available
Klioueva A
No affiliation info available
Moore A
No affiliation info available
Kelly C
No affiliation info available
Bishop C
No affiliation info available

MeSH

Adrenergic AgentsAnimalsBenzazepinesDopamine AgonistsDyskinesia, Drug-InducedLevodopaMaleMotor ActivityOxidopamineParkinsonian DisordersPyridinesRatsRats, Sprague-DawleyReceptors, Dopamine D1Serotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSeverity of Illness IndexTime Factors

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19633584

Citation

Jaunarajs, Karen L Eskow, et al. "Serotonin 1B Receptor Stimulation Reduces D1 Receptor Agonist-induced Dyskinesia." Neuroreport, vol. 20, no. 14, 2009, pp. 1265-9.
Jaunarajs KL, Dupre KB, Steiniger A, et al. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport. 2009;20(14):1265-9.
Jaunarajs, K. L., Dupre, K. B., Steiniger, A., Klioueva, A., Moore, A., Kelly, C., & Bishop, C. (2009). Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport, 20(14), 1265-9. https://doi.org/10.1097/WNR.0b013e3283300fd7
Jaunarajs KL, et al. Serotonin 1B Receptor Stimulation Reduces D1 Receptor Agonist-induced Dyskinesia. Neuroreport. 2009 Sep 23;20(14):1265-9. PubMed PMID: 19633584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. AU - Jaunarajs,Karen L Eskow, AU - Dupre,Kristin B, AU - Steiniger,Aimee, AU - Klioueva,Anna, AU - Moore,Alexander, AU - Kelly,Catherine, AU - Bishop,Christopher, PY - 2009/7/28/entrez PY - 2009/7/28/pubmed PY - 2009/10/31/medline SP - 1265 EP - 9 JF - Neuroreport JO - Neuroreport VL - 20 IS - 14 N2 - Dopamine replacement therapy for the treatment of Parkinson's disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 receptor-mediated signaling. Recent evidence suggests stimulation of striatal serotonin (5-HT) 1B receptors may reduce D1-mediated signaling. Given this potential antidyskinetic mechanism, male hemiparkinsonian Sprague-Dawley rats received treatments of D1 receptor agonist, SKF81297, (0.8 mg/kg) or L-DOPA (12 mg/kg, subcutaneous injection). Dyskinetic movements were rated using the AIMs scale. Rats were then administered vehicle (100% dimethyl sulfoxide) or the 5-HT1B receptor agonist, CP94253, (1.5 or 3.0 mg/kg, subcutaneous injection), followed by SKF81297 or L-DOPA and rated for AIMs. Results indicate that CP94253 mitigates both L-DOPA and D1 receptor agonist-induced dyskinesia. These findings suggest that 5-HT1B receptor stimulation directly diminishes D1 receptor-mediated dyskinesia, implicating an important target for the treatment of L-DOPA-induced dyskinesia. SN - 1473-558X UR - https://www.unboundmedicine.com/medline/citation/19633584/Serotonin_1B_receptor_stimulation_reduces_D1_receptor_agonist_induced_dyskinesia_ L2 - https://doi.org/10.1097/WNR.0b013e3283300fd7 DB - PRIME DP - Unbound Medicine ER -